Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus' shares shot up by 10.7% last month. Here's why.

Why Amicus Therapeutics' Stock Perked Up in June

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?

Amicus expands license agreement deal with University of Pennsylvania to develop a host of gene therapies for rare diseases.

Amicus Looks To Push Gene Therapy Pipeline After Latest Expanded Agreement

Earnings and other concerns held some stocks back Thursday.

Why NIO, PVH, and Amicus Therapeutics Slumped Today

The company announced a significant stock offering.

Here's Why Amicus Therapeutics Fell as Much as 15.6% Today

Pfizer

Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.

2 Ultra-High-Growth Biotech Stocks to Buy Now

Amicus missed Q1 revenue estimates, but Galafold's underlying growth trends remain strong.

Amicus Therapeutics: Galafold Doing Better Than Q1 Revenues Suggest

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

Amicus Therapeutics successfully launched the first chaperone medicines (i.e. Galafold) to manage Fabry disease. Therefore, the chances of success for subsequent molecules are quite favorable.

Amicus Therapeutics: Galvanizing Growth By Capturing The Tides Of Gene Therapy

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2019 Results - Earnings Call Transcript

Five Below

TPI Composites

These growth companies could make a killing if their big bets pay off.

Three Growth Stocks to Buy and Hold for the Next 50 Years.

There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. has reported pre-clinical data from its Pompe disease gene therapy program and the results will be presented in the poster session at the ASGCT annual meeting on Tuesday.

Potentially Good News for Those Who Suffer From Pompe Disease

Amicus Therapeutics has significantly transformed over the last few years.

Amicus Therapeutics: Looking A Few Years Ahead

Amicus Therapeutics, Inc. has an extensive portfolio of novel therapies for rare diseases with a focus on lysosomal storage disorders, according to Janney Montgomery Scott.

News for Amicus Therapeutics Stock (FOLD)